# MannKind Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/MannKind Corporation). ## Overview MannKind Corp is a biopharmaceutical company focused on developing and commercializing inhaled and other specialty therapies, with a commercial base in diabetes and cardiopulmonary care. Its portfolio includes Afrezza, an inhaled mealtime insulin, V-Go, a wearable insulin delivery device, and Furoscix, a subcutaneous furosemide therapy for fluid overload conditions, alongside collaboration and royalty revenue tied to partner products. ## Products & services • Afrezza inhaled insulin for mealtime glucose control • V-Go wearable insulin delivery device • Furoscix for outpatient fluid overload treatment • Collaboration, manufacturing and service revenue • Royalty revenue from Tyvaso DPI sales - **Commercial diabetes products** (45%) — Includes Afrezza and V-Go, which are sold to support insulin therapy in diabetes care. - **Cardiopulmonary therapy** (10%) — Includes Furoscix, used for outpatient treatment of fluid overload and heart-failure-related conditions. - **Collaboration and manufacturing services** (25%) — Includes product sold to partners, contract manufacturing, and related service revenue. - **Royalties** (20%) — Includes royalty income from partner commercial sales, especially Tyvaso DPI. - Afrezza inhaled rapid-acting insulin for mealtime use - V-Go wearable insulin delivery device for basal-bolus therapy - Furoscix furosemide delivery system for fluid overload - Manufacturing and service revenue from collaboration partners - Royalty income tied to Tyvaso DPI net sales ## Customers MannKind sells mainly through a limited set of wholesale distributors, specialty and retail pharmacies, durable medical suppliers, specialty distributors, and direct purchasers in the U.S. and India. Its end customers are patients and healthcare providers in diabetes and cardiopulmonary care, while collaboration revenue depends on commercial partners and their downstream sales performance. - **Wholesale distributors** (primary) — Buy commercial products in bulk and resell into pharmacy and care channels; important for broad U.S. access. - **Specialty and retail pharmacies** (primary) — Dispense Afrezza and related therapies to patients and help drive prescription fulfillment. - **Durable medical suppliers and specialty distributors** (secondary) — Purchase V-Go and similar products for distribution into diabetes care channels. - **Direct purchasers** (secondary) — Buy directly in the U.S. and India, supporting localized commercial access. - **Collaboration partners** (primary) — Buy manufacturing, service, or product supply tied to partnered programs and royalty streams. - Wholesale distributors that resell to pharmacies and care settings - Specialty pharmacies serving patients needing chronic therapy - Durable medical suppliers and specialty distributors for device-based products - Direct purchasers in the U.S. and India - Collaboration partners that buy product or services for commercialization ## Geography The company’s commercial revenue is concentrated in the United States, with additional direct customer activity in India and partner-related revenue tied to U.S. commercialization. Manufacturing and operations are centered in the U.S., including Danbury, Connecticut, which matters because supply continuity, regulatory compliance, and tariff exposure can affect product availability and cost. - United States is the core commercial and manufacturing market - India is a disclosed direct customer market for product sales - Danbury, Connecticut is a key manufacturing location - Partner revenue is linked to U.S. sales of Tyvaso DPI - Trade policy and tariffs can affect imported raw materials and components ## Strategy MannKind is focused on expanding adoption of its approved products while maintaining the manufacturing and commercial infrastructure needed to support them. It is also reliant on collaboration economics, especially royalty and service revenue tied to Tyvaso DPI, so partner execution and partner product demand are central to its strategy. - **Expand commercial execution for approved products** (short-term) — Revenue depends on prescription uptake and channel access for Afrezza, V-Go and Furoscix. - **Protect and grow collaboration revenue** (medium-term) — Royalty and manufacturing income from UT is a meaningful revenue stream and depends on partner sales. - **Improve manufacturing and supply resilience** (short-term) — Commercial success depends on sufficient output and reliable sourcing of materials and components. - Grow adoption of Afrezza, V-Go and Furoscix - Strengthen sales force coverage across physician target groups - Improve manufacturing reliability and supply continuity - Capture more value from collaboration, royalty and service revenue - Mitigate tariff and sourcing risk for raw materials and components ## Risks The company faces commercialization risk because its products may achieve only limited market acceptance, particularly in competitive diabetes and heart-failure markets. It is also exposed to manufacturing, supplier, reimbursement, and partner-dependence risks, since revenue can be affected by production shortfalls, payer coverage, and strategic decisions made by collaborators such as United Therapeutics. - **Limited commercial success of approved products** [high] — Afrezza, V-Go and Furoscix compete against entrenched therapies and may not achieve broad uptake. - **Manufacturing and supply chain disruption** [high] — The company must manufacture sufficient quantities and source materials reliably to support sales. - **Payer coverage and reimbursement pressure** [high] — If third-party payers do not cover products, prescriptions and sales can fall materially. - **Partner concentration and dependence on United Therapeutics** [high] — Royalty and collaboration revenue depend on UT's sales and strategic priorities. - **Tariff and trade policy exposure** [medium] — Higher import costs for raw materials and components could pressure gross margin. - Products may not gain broad physician, payer, or patient acceptance - Manufacturing disruptions could limit supply and hurt margins - Supplier failures or tariffs could raise costs and delay output - Reimbursement and pricing pressure can reduce prescription demand - Revenue is exposed to United Therapeutics' commercial decisions - Competition from larger pharma companies may pressure share and pricing ## Accounting Revenue recognition is a key accounting issue because product sales are recorded net of rebates, chargebacks, discounts, returns, and other variable consideration, which requires judgment and can materially change reported revenue. Investors should also watch collaboration accounting, royalty recognition, and estimates tied to acquired intangibles, contingent consideration, and stock-based compensation, all of which can affect earnings volatility and comparability. - **Revenue recognition and gross-to-net reserves** — Can materially affect reported revenue and receivables - **Royalty revenue from Tyvaso DPI** — Creates earnings sensitivity to partner sales trends - **Collaboration and deferred revenue** — Can cause quarter-to-quarter revenue volatility - **Business combinations and acquired intangibles** — Can affect amortization and impairment charges - **Stock-based compensation** — Affects operating expense and reported profitability - Net revenue depends on gross-to-net reserve estimates - Rebates, chargebacks and returns can materially reduce reported sales - Royalty revenue depends on partner sales timing and reporting - Collaboration revenue may include deferred revenue recognition - Acquired intangibles and contingent consideration require valuation judgment --- *Last updated: 2026-04-28T20:24:06.638404+00:00*